Literature DB >> 20726719

Aurora-a contributes to radioresistance by increasing NF-kappaB DNA binding.

Eun-Taex Oh1, Mi-Sun Byun, Hyemi Lee, Moon-Taek Park, Dae-Myung Jue, Chang-Woo Lee, Byung Uk Lim, Heon Joo Park.   

Abstract

Aurora-A, a serine/threonine kinase that is overexpressed in certain human cancer cell lines, plays an important role in mitotic progression. Aurora-A has also been reported to be involved in the activation of nuclear factor kappa B (NF-kappaB). The purpose of the present study was to identify the role of Aurora-A in the radiation-induced activation pathway of NF-kappaB. Wild-type and Aurora-A knockdown (Aurora-A(KD)) HeLa cells were irradiated with 4 Gy of gamma rays and the EMSA, luciferase reporter gene assay and immunoblot analysis were performed. The siRNA-based gene knockdown and overexpression system was adopted to elucidate the role of Aurora-A in radiation-induced NF-kappaB pathway activation. The clonogenic survival study indicated that Aurora-A(KD) cells and the wild-type cells transfected with Aurora-A siRNA or RelA/p65 siRNA were more radiosensitive than the wild-type cells. In both the wild-type and Aurora-A(KD) cells, radiation caused IkappaB kinase-mediated phosphorylation, degradation of IkappaBalpha and phosphorylation of RelA/p65. The nuclear translocation of RelA/p65 was also similar in the wild-type and Aurora-A(KD) cells. However, RelA/p65-DNA binding was markedly suppressed in Aurora-A(KD) cells compared to that in wild-type cells. It was concluded that Aurora-A enhances the binding of NF-kappaB to DNA, thereby increasing the gene transcription by NF-kappaB and decreasing the radiosensitivity of the cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20726719     DOI: 10.1667/RR2017.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  5 in total

1.  Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.

Authors:  Eun-Taex Oh; Moon-Taek Park; Bo-Hwa Choi; Seonggu Ro; Eun-Kyung Choi; Seong-Yun Jeong; Heon Joo Park
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

2.  The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.

Authors:  Xin Jin; Qingqing Mo; Yu Zhang; Yue Gao; Yuan Wu; Jing Li; Xing Hao; Ding Ma; Qinglei Gao; Pingbo Chen
Journal:  Cancer Biol Ther       Date:  2016-05-03       Impact factor: 4.742

3.  Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis.

Authors:  Yuhua Ma; Jie Yang; Ruozheng Wang; Zegao Zhang; Xiaoli Qi; Chunhua Liu; Miaomiao Ma
Journal:  Oncotarget       Date:  2017-05-09

Review 4.  Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.

Authors:  Dauren Alimbetov; Sholpan Askarova; Bauyrzhan Umbayev; Terence Davis; David Kipling
Journal:  Int J Mol Sci       Date:  2018-06-06       Impact factor: 5.923

5.  A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.

Authors:  Justin A Chen; Jasmine C Huynh; Chun-Yi Wu; Ai-Ming Yu; Karen Matsukuma; Thomas J Semrad; David R Gandara; Tianhong Li; Jonathan W Riess; Kit Tam; Philip C Mack; Anthony Martinez; Nichole Mahaffey; Karen L Kelly; Edward J Kim
Journal:  Cancer Chemother Pharmacol       Date:  2022-07-30       Impact factor: 3.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.